NutriBand Inc. NTRB
of transdermal pharmaceutical products. Our development pipeline primarily consists of transdermal products that are based on our proprietary
AVERSA™ abuse deterrent transdermal technology that we believe can be incorporated into existing transdermal patches
that contain drugs that are susceptible to abuse and misuse such as opioid and stimulant drugs.
services through our subsidiaries Pocono Pharmaceuticals operating as Active Intelligence and 4P Therapeutics. Pocono Pharmaceuticals
Valuation FY2026 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $2.0M | $2.1M | $2.1M | $2.1M | $1.2M | $737.5K | $370.6K | $245.3K | — |
| Cost of revenue | — | $1.5M | $1.4M | $1.2M | $1.3M | $917.8K | $627.4K | $549.1K | $288.3K | — |
| Gross profit | — | $566.3K | $743.3K | $862.1K | $750.4K | $554.3K | $316.2K | -$178.5K | -$43.0K | — |
| R&D | — | $1.9M | $3.1M | $2.0M | $982.2K | $411.4K | — | — | — | — |
| SG&A | — | $7.0M | $4.3M | $3.8M | $3.9M | $4.0M | $2.9M | $1.8M | $3.3M | $171.9K |
| Total operating expenses | — | $8.9M | $11.0M | $5.7M | $6.6M | $7.5M | $2.9M | $2.3M | $3.6M | $2.7M |
| Operating income | — | -$8.3M | -$10.3M | -$4.9M | -$4.5M | -$6.1M | -$2.6M | -$2.0M | -$3.3M | -$2.7M |
| Interest expense | — | $22.5K | $21.4K | $75.8K | $8.3K | $118.4K | $280.7K | $73.4K | — | — |
| Pre-tax income | — | -$8.2M | -$10.5M | -$5.5M | -$4.5M | -$6.2M | -$2.9M | -$2.7M | -$3.3M | -$2.7M |
| Net income | — | -$8.2M | -$10.5M | -$5.5M | -$4.5M | -$6.2M | -$2.9M | -$2.7M | -$3.3M | -$2.7M |
| EPS, basic | — | -2.58 | -0.99 | -0.69 | -0.53 | -0.80 | -0.51 | — | — | — |
| EPS, diluted | — | -2.58 | -0.99 | -0.69 | -0.53 | -0.80 | -0.51 | -0.50 | -0.62 | -0.14 |
| Shares, diluted (wtd. avg.) | — | $11.6M | $10.6M | $8.0M | $8.5M | $7.9M | $5.8M | — | — | — |
Balance sheet
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | — | $4.6M | $4.3M | $492.9K | $2.0M | $4.9M | $152.0K | $10.2K | $474.7K | — |
| Receivables | — | $118.4K | $73.8K | $148.6K | $113.0K | $71.4K | $109.3K | $12.8K | $13.1K | — |
| Inventory | — | $118.0K | $212.0K | $168.6K | $229.3K | $131.6K | $52.8K | — | — | $4.1K |
| Total current assets | — | $5.0M | $4.8M | $1.0M | $2.7M | $5.5M | $314.2K | $43.2K | $590.5K | $164.9K |
| Property, plant and equipment | — | $567.3K | $695.1K | $774.9K | $897.7K | $979.3K | $1.1M | $111.0K | $146.1K | — |
| Goodwill | — | $1.7M | $1.7M | $5.0M | $5.0M | $5.3M | $7.5M | $1.7M | $1.7M | — |
| Other intangibles | — | $200.4K | $261.1K | $667.3K | $780.4K | $926.9K | $1.0M | $314.7K | $351.8K | — |
| Total assets | — | $7.5M | $7.5M | $7.5M | $9.5M | $12.7M | $9.9M | $2.2M | $2.8M | $164.9K |
| Accounts payable | — | $502.7K | $698.8K | $680.1K | $534.7K | $639.5K | $940.6K | $771.9K | $291.8K | $12.3K |
| Short-term debt | — | — | — | $2.0M | — | — | — | — | $0 | $1.8K |
| Total current liabilities | — | $784.3K | $982.8K | $999.1K | $748.6K | $779.3K | $2.6M | $2.0M | $403.0K | $43.4K |
| Long-term debt | — | — | — | — | — | — | — | — | — | $1.8K |
| Total liabilities | — | $868.4K | $1.0M | $1.1M | $883.4K | $880.4K | $2.8M | $2.0M | — | — |
| Retained earnings | — | -$46.7M | -$38.5M | -$28.0M | -$22.5M | -$18.0M | -$11.8M | -$8.9M | -$6.2M | -$2.8M |
| Total equity | — | $6.7M | $6.4M | $6.4M | $8.6M | $11.9M | $7.1M | $175.4K | $2.4M | $121.5K |
Cash flow
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | — | -$5.1M | -$4.6M | -$3.5M | -$3.0M | -$2.8M | -$297.1K | -$894.5K | -$1.1M | -$92.9K |
| Depreciation and amortisation | — | $133.1K | $171.9K | $174.6K | $330.1K | $308.7K | $160.1K | $91.3K | $37.0K | $0 |
| Stock-based compensation | — | $2.6M | $1.4M | $499.9K | $732.1K | $365.0K | $2.0M | $252.7K | $1.8M | — |
| Capital expenditure | — | $5.3K | $92.0K | $51.8K | $79.3K | $81.6K | — | — | $4.2K | — |
| Investing cash flow | — | -$5.3K | -$92.0K | -$51.8K | -$79.3K | -$81.6K | $67.0K | — | -$404.2K | — |
| Financing cash flow | — | $5.4M | $8.5M | $2.1M | $160.1K | $7.6M | $371.9K | $430.2K | $2.0M | $65.8K |
| Buybacks | — | — | $148.5K | — | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-058507.
Others in SIC 3842
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| ISRG | INTUITIVE SURGICAL INC | $129.55B | 46.6x | 20.5% |
| EW | Edwards Lifesciences Corp | $51.82B | 49.1x | 11.5% |
| STE | STERIS plc | $21.90B | 28.3x | 8.7% |
| ZBH | ZIMMER BIOMET HOLDINGS, INC. | $18.71B | 27.6x | 7.2% |
| ALGN | ALIGN TECHNOLOGY INC | $11.27B | 28.1x | 0.9% |
| MSA | MSA Safety Inc | $7.28B | 26.6x | 3.7% |
| ESTA | ESTABLISHMENT LABS HOLDINGS INC. | $2.21B | — | 27.1% |
| CDRE | Cadre Holdings, Inc. | $1.27B | 29.2x | 7.5% |